Giovanni Musso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6496164/publications.pdf

Version: 2024-02-01

76 papers	9,921 citations	76326 40 h-index	76900 74 g-index
79 all docs	79 docs citations	79 times ranked	13204 citing authors

#	Article	IF	Citations
1	Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine, 2011, 43, 617-649.	3.8	1,098
2	Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology, 2002, 35, 367-372.	7.3	644
3	Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology, 2003, 37, 909-916.	7.3	621
4	Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in Lipid Research, 2009, 48, 1-26.	11.6	564
5	Obesity, Diabetes, and Gut Microbiota. Diabetes Care, 2010, 33, 2277-2284.	8.6	557
6	Interactions Between Gut Microbiota and Host Metabolism Predisposing to Obesity and Diabetes. Annual Review of Medicine, 2011, 62, 361-380.	12.2	515
7	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Medicine, 2014, 11, e1001680.	8.4	507
8	A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 79-104.	7.3	492
9	Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nature Reviews Drug Discovery, 2016, 15, 249-274.	46.4	365
10	Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis. JAMA Internal Medicine, 2017, 177, 633.	5.1	339
11	Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Progress in Lipid Research, 2013, 52, 175-191.	11.6	326
12	Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology, 2005, 42, 1175-1183.	7.3	253
13	A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Annals of Medicine, 2012, 44, 375-393.	3.8	247
14	Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. Gastroenterology, 2018, 155, 282-302.e8.	1.3	216
15	Hypoadiponectinemia Predicts the Severity of Hepatic Fibrosis and Pancreatic Beta-Cell Dysfunction in Nondiabetic Nonobese Patients with Nonalcoholic Steatohepatitis. American Journal of Gastroenterology, 2005, 100, 2438-2446.	0.4	185
16	Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome?. Diabetes Care, 2008, 31, 562-568.	8.6	185
17	Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Current Opinion in Lipidology, 2010, 21, 76-83.	2.7	151
18	Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?. Current Diabetes Reports, 2018, 18, 98.	4.2	138

#	Article	IF	Citations
19	Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. Diabetes Care, 2016, 39, 1830-1845.	8.6	129
20	Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities. Antioxidants and Redox Signaling, 2011, 15, 1325-1365.	5.4	128
21	Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology, 2008, 47, 1167-1177.	7.3	119
22	Consuming More of Daily Caloric Intake at Dinner Predisposes to Obesity. A 6-Year Population-Based Prospective Cohort Study. PLoS ONE, 2014, 9, e108467.	2.5	117
23	Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH?. Hepatology, 2007, 45, 1097-1107.	7.3	112
24	Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology, 2012, 56, 933-942.	7.3	110
25	Obstructive Sleep Apnea Syndrome Affects Liver Histology and Inflammatory Cell Activation in Pediatric Nonalcoholic Fatty Liver Disease, Regardless of Obesity/Insulin Resistance. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 66-76.	5.6	103
26	Emerging Liverâ€“Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends in Molecular Medicine, 2015, 21, 645-662.	6.7	96
27	Prolonged saturated fatâ€“induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. American Journal of Clinical Nutrition, 2009, 89, 558-567.	4.7	90
28	Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids, 2001, 36, 1117-1124.	1.7	83
29	Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease. Annual Review of Medicine, 2010, 61, 375-392.	12.2	77
30	Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology, 2009, 49, 426-435.	7.3	75
31	Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2019, 365, l1328.	2.3	74
32	Obstructive Sleep Apnea-Hypopnea Syndrome and Nonalcoholic Fatty Liver Disease: Emerging Evidence and Mechanisms. Seminars in Liver Disease, 2012, 32, 049-064.	3.6	71
33	Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends in Molecular Medicine, 2013, 19, 522-535.	6.7	68
34	Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism. Diabetes, 2013, 62, 1109-1120.	0.6	61
35	Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacological Research, 2019, 144, 390-408.	7.1	54
36	Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. American Journal of Clinical Nutrition, 2007, 86, 661-671.	4.7	52

#	Article	IF	Citations
37	Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort. American Journal of Clinical Nutrition, 2012, 96, 962-969.	4.7	50
38	Altered gutâ€“liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver. Thorax, 2015, 70, 769-781.	5.6	47
39	Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. American Journal of Clinical Nutrition, 2013, 98, 895-906.	4.7	43
40	Diabetic ketoacidosis with SGLT2 inhibitors. BMJ, The, 2020, 371, m4147.	6.0	42
41	Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease. Current Opinion in Lipidology, 2011, 22, 489-496.	2.7	41
42	OSAS-Related Inflammatory Mechanisms of Liver Injury in Nonalcoholic Fatty Liver Disease. Mediators of Inflammation, 2015, 2015, 1-10.	3.0	41
43	A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Review of Gastroenterology and Hepatology, 2021, 15, 345-352.	3.0	41
44	TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. Journal of Lipid Research, 2017, 58, 1221-1229.	4.2	40
45	Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2019, 20, 1745.	4.1	39
46	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 106-120.	6.1	37
47	Lipoprotein metabolism mediates the association of MTP polymorphism with Î²-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. Journal of Nutritional Biochemistry, 2010, 21, 834-840.	4.2	36
48	Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution. Trends in Pharmacological Sciences, 2018, 39, 387-401.	8.7	36
49	Probiotics, Prebiotics, Energy Balance, and Obesity. Gastroenterology Clinics of North America, 2012, 41, 843-854.	2.2	34
50	Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. Hepatology, 2010, 51, 715-717.	7.3	32
51	Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. PLoS Medicine, 2020, 17, e1003461.	8.4	28
52	Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease. Hepatology, 2012, 56, 788-789.	7.3	27
53	New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitisâ€“Related Kidney Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 972-985.	4.4	26
54	Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation. American Journal of Gastroenterology, 2019, 114, 607-619.	0.4	22

#	Article	IF	Citations
55	Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. Annals of Medicine, 2008, 40, 383-394.	3.8	21
56	Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. American Journal of Clinical Nutrition, 2011, 94, 1033-1042.	4.7	21
57	Early prolonged prone position in noninvasively ventilated patients with SARS-CoV-2-related moderate-to-severe hypoxemic respiratory failure: clinical outcomes and mechanisms for treatment response in the PRO-NIV study. Critical Care, 2022, 26, 118.	5.8	21
58	MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. Human Molecular Genetics, 2017, 26, 1747-1758.	2.9	20
59	Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression?. Journal of Gastroenterology, 2009, 44, 476-482.	5.1	16
60	Transcription Factor 7-Like 2 (TCF7L2) Polymorphism and Hyperglycemia in an Adult Italian Population-Based Cohort. Diabetes Care, 2010, 33, 1233-1235.	8.6	15
61	The Finnish Diabetes Risk Score (FINDRISC) and other non-invasive scores for screening of hepatic steatosis and associated cardiometabolic risk. Annals of Medicine, 2011, 43, 413-417.	3.8	15
62	TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD. Journal of Hepatology, 2016, 64, 979-981.	3.7	15
63	Non-alcoholic fatty liver, adipose tissue, and the bone: a new triumvirate on the block. Endocrine, 2012, 42, 237-239.	2.3	14
64	Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?. Current Pharmaceutical Design, 2013, 19, 5297-313.	1.9	11
65	Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH. Hepatology, 2006, 43, 1169-1170.	7.3	10
66	Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD?. Diabetologia, 2014, 57, 850-855.	6.3	10
67	Chronic kidney disease (CKD) and NAFLD: Time for awareness and screening. Journal of Hepatology, 2015, 62, 983-984.	3.7	10
68	Need for a three-focused approach to nonalcoholic fatty liver disease. Hepatology, 2011, 53, 1773-1773.	7.3	9
69	Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: All that is gold does not glitter, not all those who wander are lost. Hepatology, 2015, 61, 2104-2106.	7.3	8
70	Isoleucine-to-methionine substitution at residue 148 variant of PNPLA3 gene and metabolic outcomes in gestational diabetes. American Journal of Clinical Nutrition, 2015, 101, 310-318.	4.7	6
71	Trials of obeticholic acid for non-alcoholic steatohepatitis. Lancet, The, 2015, 386, 27.	13.7	6
72	Gut Microbiota as a Modulator of Cardiometabolic Risk: Mechanisms and Therapeutic Implications. Current Cardiovascular Risk Reports, 2012, 6, 71-79.	2.0	2

#	Article	IF	Citations
73	The Postprandial Phase as a Link Between Systemic Lipid Peroxidation and Liver Injury in NASH This article has been retracted. American Journal of Gastroenterology, 2006, .	0.4	2
74	NAFLD: Old Issues and Emerging Concepts. Seminars in Liver Disease, 2012, 32, 001-002.	3.6	1
75	Letter by Musso et al Regarding Article, â€œCardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitusâ€. Circulation, 2017, 136, 1563-1564.	1.6	0
76	MICROBIOTA INTESTINALE E RISCHIO CARDIOVASCOLARE. Il Diabete, 2019, 3, .	0.0	0